Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Consolidated Net Income: 2019-2024

Historic Consolidated Net Income for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to -$334.7 million.

  • Lyell Immunopharma's Consolidated Net Income rose 23.69% to -$34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$327.6 million, marking a year-over-year decrease of 71.61%. This contributed to the annual value of -$334.7 million for FY2024, which is 49.71% down from last year.
  • As of FY2024, Lyell Immunopharma's Consolidated Net Income stood at -$334.7 million, which was down 49.71% from -$223.6 million recorded in FY2023.
  • In the past 5 years, Lyell Immunopharma's Consolidated Net Income ranged from a high of -$180.0 million in FY2022 and a low of -$334.7 million during FY2024.
  • In the last 3 years, Lyell Immunopharma's Consolidated Net Income had a median value of -$223.6 million in 2023 and averaged -$246.1 million.
  • Per our database at Business Quant, Lyell Immunopharma's Consolidated Net Income plummeted by 119.22% in 2020 and then increased by 15.73% in 2022.
  • Yearly analysis of 5 years shows Lyell Immunopharma's Consolidated Net Income stood at -$206.0 million in 2020, then fell by 3.70% to -$213.6 million in 2021, then rose by 15.73% to -$180.0 million in 2022, then decreased by 24.19% to -$223.6 million in 2023, then plummeted by 49.71% to -$334.7 million in 2024.